Cerevel Therapeutics Holdings, Inc. (CERE)
| Market Cap | 5.44B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -199.08M |
| Shares Out | 144.87M |
| EPS (ttm) | -1.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,631,412 |
| Open | 36.75 |
| Previous Close | 36.48 |
| Day's Range | 35.63 - 37.99 |
| 52-Week Range | 9.00 - 37.99 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 33.00 (-12.2%) |
| Est. Earnings Date | Nov 11, 2021 |
About CERE
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing CVL-231, a positive allosteric modulator (PAM) that is in Phase Ib clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as Phase I proof-of-principle trial for acute anxiety. The company's products also comprise Tavapadon, a se...
Financial Performance
Financial StatementsNews
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fid...
New York, New York--(Newsfile Corp. - September 15, 2021) - Levi & Korsinsky announces it has commenced an investigation of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) concerning possible breache...
Cerevel Therapeutics to Host Virtual R&D Event on October 7
Event will focus on CVL-871, a D1/D5 partial agonist in development for dementia-related apathy, and will include an update on CVL-231, an M4 positive allosteric modulator for the treatment of schizophr...
3 Biotech Stocks That Soared to New Heights Last Week
Find out what these industry favorites are doing to impress investors.
3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Should Investors Follow Private Equity into Life Sciences?
Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new fun...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fid...
New York, New York--(Newsfile Corp. - August 12, 2021) - Levi & Korsinsky announces it has commenced an investigation of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) concerning possible breaches o...
Cerevel Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates
Announced positive topline results for CVL-231 in Phase 1b trial in schizophrenia
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fi...
New York, New York--(Newsfile Corp. - August 2, 2021) - Levi & Korsinsky announces it has commenced an investigation of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) concerning possible breaches of...
Cerevel Therapeutics Announces Redemption of Public Warrants
CAMBRIDGE, Mass., July 30, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE; CEREW) (the “Company”), a company dedicated to unraveling the mysteries of the brain to treat neuroscience disease...
Cerevel Therapeutics to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it w...
Why Cerevel Therapeutics Is Up More Than 29% in the First Half of 2021
A positive early stage trial for a schizophrenia drug has pushed this biotech's stock this year.
New Analyst Coverage Puts Spotlight on These 4 Stocks
Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like HIBB, ITGR, CERE and ATEN.
Here's What's Pushing Cerevel Therapeutics Stock Lower Today
Investors aren't thrilled about how this biotech intends to pay operating expenses that are about to balloon.
Cerevel Therapeutics Announces Pricing of $350 Million Public Offering of Common Stock
CAMBRIDGE, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the ...
Cerevel (CERE) Novel Schizophrenia Drug Succeeds in Phase I
Cerevel Therapeutics (CERE) surges as schizophrenia candidate, CVL-231, demonstrates clinically meaningful and statistically significant improvement in PANSS Total score at 6 weeks in phase Ia study.
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that...
CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing
Cerevel Therapeutics is taking on schizophrenia with its newest drug treatment. After posting positive trial results, CERE stock is up big.
These 2 Nasdaq Biotechs Made Eye-Popping Moves Tuesday
You might not have heard of them, but one went up big while the other served up a massive disappointment.
Here's Why Cerevel Therapeutics Stock Is Shooting Through the Roof Today
Positive topline results from the company's schizophrenia candidate were better than expected.
Cerevel Therapeutics Announces Positive Topline Results for CVL-231 in Phase 1b Clinical Trial in Patients with Schiz...
Both doses of CVL-231 demonstrated a clinically meaningful and statistically significant improvement in PANSS Total score at 6 weeks and were overall well-tolerated compared with placebo
Cerevel Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to CVL-871 for the Treatment of Dementi...
CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that the U...
Cerevel Therapeutics to Present at Upcoming Virtual Investor Conferences
CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that it wil...
Cerevel Therapeutics Reports First Quarter 2021 Financial Results and Business Updates
Announced strategic $125 million non-dilutive financing for tavapadon
Cerevel Therapeutics to Report First Quarter 2021 Financial Results on Monday, May 17, 2021
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it...
Cerevel Therapeutics Appoints Abraham N. Ceesay as President
CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of...